Scientists discover why ribosomes misread certain modified mRNA sequences and show how simple sequence changes could improve vaccine design and safety.
Zacks Investment Research on MSN
MRNA stock gains over $4B in a week: Time to buy, hold or sell?
Shares of Moderna MRNA have gained more than 5% over the past week, adding roughly $4.2 billion in market value. The upside ...
Add Yahoo as a preferred source to see more of our stories on Google. With a little help, your immune cells can be potent tumor killers. Steve Gschmeissner/Science Photo Library via Getty Images The ...
LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...
The mass-produced COVID-19 vaccines built using the mRNA model – which were rapidly manufactured during the global pandemic – could also help the immune system recognise and attack cancer tumours, new ...
Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.
Researchers from Tel Aviv University and the Israel Institute for Biological Research in Ness Ziona have used the platform developed for COVID-19 vaccines to create the world's first mRNA-based ...
COVID-19 vaccines from Pfizer and Moderna should be pulled from circulation, a former Centers for Disease Control and Prevention official said in a new interview. “I really would like to see the mRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results